This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
by Zacks Equity Research
Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.
PBYINegative Net Change RGENPositive Net Change ANIKNegative Net Change PGENNegative Net Change
biotechs
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?
by Kanishka Das
NTLA wins FDA priority review for lonvo-z, with a March 10, 2027 decision, potentially adding its first product, while nex-z studies are progressing well.
NTLAPositive Net Change REGNPositive Net Change BEAMPositive Net Change CRSPPositive Net Change
biotechs
Novo Expands AI Push With Anthropic Deal to Accelerate Drug Discovery
by Zacks Equity Research
NVO is expanding its AI strategy with Anthropic to tackle drug discovery challenges, boost R&D productivity and develop new medicines faster.
NVONegative Net Change ALDXNegative Net Change ACIUPositive Net Change PGENNegative Net Change
artificial-intelligence biotechnology biotechs medical pharmaceuticals
Novo Falls 5% in a Week: How Should Investors Approach the Stock Now?
by Ahan Chakraborty
NVO's 5% drop in a week reflects intensifying GLP-1 competition and semaglutide risks, but its broad pipeline offers potential long-term growth.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Is CRBP a Good Cannabis Investment After Positive Obesity Study Data?
by Sundeep Ganoria
Corbus Pharmaceuticals' positive obesity data boosts its cannabinoid strategy, while CRB-701 and cash needs add key context for investors.
CRBPPositive Net Change SNYPositive Net Change NVONegative Net Change LLYPositive Net Change
biotechs medical pharmaceuticals
New Strong Buy Stocks for September 17th
by Zacks Equity Research
MOV, MAX, MTG, ASMB and MSGM have been added to the Zacks Rank #1 (Strong Buy) List on September 17th, 2026.
MTGNegative Net Change MOVNegative Net Change ASMBPositive Net Change MAXPositive Net Change MSGMPositive Net Change
biotechs consumer-discretionary insurance
BioMarin Stops Voxzogo Development for Noonan Syndrome
by Zacks Equity Research
BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.
BMRNPositive Net Change ASNDPositive Net Change BBIONegative Net Change
biotechs medical
How AbbVie's Neuroscience Portfolio Has Transformed Over the Years
by Sundeep Ganoria
ABBV's neuroscience portfolio has broadened across psychiatry, migraine and Parkinson's, driving strong growth and raising its 2026 outlook.
ABBVPositive Net Change BIIBPositive Net Change JNJNegative Net Change
biotechs medical pharmaceuticals
RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
by Zacks Equity Research
Rocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion.
RCKTNegative Net Change RGENPositive Net Change AMRNNegative Net Change ANIKNegative Net Change
biotechs
Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America
by Zacks Equity Research
GILD's PAHO deal expands twice-yearly lenacapavir access across Latin America and the Caribbean, adding 14 countries to its global access strategy.
GILDPositive Net Change ALDXNegative Net Change ACIUPositive Net Change PGENNegative Net Change
biotechnology biotechs medical pharmaceuticals